|
|
Article: Study compares weekly dosing efficacies of Fosamax and Actonel.
- Article from:
- Life Science Weekly
- Article date:
- October 19, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 OCT 19 - (NewsRx.com & NewsRx.net) -- Fosamax Once Weekly (alendronate sodium) increased bone mineral density (BMD) more than Actonel Once-a-Week (risedronate) with similar tolerability, according to results of the Fosamax Actonel Comparison Trial (FACT) .
This is the first U.S. head-to-head study comparing U.S. Food and Drug Administration-approved once-weekly osteoporosis treatments in postmenopausal women with osteoporosis.
In this study, Fosamax provided greater increases in BMD at all sites measured as early as 6 months, and lowered levels of biochemical markers of bone turnover further within the normal pre-menopausal range than Actonel within ...